Article

Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis

Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain.
Diagnostic microbiology and infectious disease (Impact Factor: 2.57). 04/2012; 73(1):57-64. DOI: 10.1016/j.diagmicrobio.2012.01.012
Source: PubMed

ABSTRACT The virulence factor gliotoxin (GT) and its inactive derivative, bis(methylthio)gliotoxin (bmGT), are produced by pathogens of the genus Aspergillus. Here we report the detection of GT and bmGT in serum of humans at risk of invasive aspergillosis (IA) as well as in cultures of fungal isolates derived from patients with proven infection with A. fumigatus. Although both compounds are readily recoverable from spiked human serum or plasma, only bmGT is retained in whole blood, indicating that bmGT may be the better marker for in vivo detection. Accordingly, bmGT was found more frequently than GT in samples from patients at risk of IA and incultures of clinical isolates of A. fumigatus. In some cases, bmGT was detected before mycologic evidence ofinfection was gained. Importantly, neither GT nor bmGT was found in serum from healthy donors or from neutropenic patients without any sign of infection. Thus, bmGT presence might provide a more reliable indicator of A. fumigatus infections than GT. Due to its simplicity and sensitivity, a diagnostic technology based on this test could be easily adopted in clinical laboratories to help in the diagnosis of this often fatal fungal infection.

Download full-text

Full-text

Available from: Jacques Meis, Jul 07, 2015
0 Followers
 · 
242 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive aspergillosis (IA) is a life-threatening complication of haematological malignancy and haematopoietic stem cell transplantation caused by the ubiquitous fungus Aspergillus. Current diagnosis of IA is multifaceted relying on data from clinical, radiological, and microbiological sources. The detection of Aspergillus biomarkers provides strategies both to pre-empt and to exclude disease, but the choice of biomarker assays is limited, requiring specialist equipment and training. This review examines recent advances in the accurate diagnosis of IA through the development of an Aspergillus lateral-flow device (LFD) incorporating a monoclonal antibody, JF5, which detects an antigenic marker of active infection. Recent trials using bronchoalveolar lavage fluids and serum samples from humans and from animal models of disease, have demonstrated the utility of the LFD as a rapid and user-friendly adjunct test for the quick and accurate diagnosis of pulmonary infections.
    Current Fungal Infection Reports 09/2013; 7(3). DOI:10.1007/s12281-013-0138-x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive aspergillosis (IA), an infection caused by fungi in the genus Aspergillus, is seen in patients with immunological deficits, particularly acute leukaemia and stem cell transplantation, and has been associated with high rates of mortality in previous years. Diagnosing IA has long been problematic owing to the inability to culture the main causal agent A. fumigatus from blood. Microscopic examination and culture of respiratory tract specimens have lacked sensitivity, and biopsy tissue for histopathological examination is rarely obtainable. Thus, for many years there has been a great interest in nonculture-based techniques such as the detection of galactomannan, β -D-glucan, and DNA by PCR-based methods. Recent meta-analyses suggest that these approaches have broadly similar performance parameters in terms of sensitivity and specificity to diagnose IA. Improvements have been made in our understanding of the limitations of antigen assays and the standardisation of PCR-based DNA detection. Thus, in more recent years, the debate has focussed on how these assays can be incorporated into diagnostic strategies to maximise improvements in outcome whilst limiting unnecessary use of antifungal therapy. Furthermore, there is a current interest in applying these tests to monitor the effectiveness of therapy after diagnosis and predict clinical outcomes. The search for improved markers for the early and sensitive diagnosis of IA continues to be a challenge.
    01/2013; 2013:459405. DOI:10.1155/2013/459405
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dimeric basic leucine zipper (bZIP) proteins are conserved transcriptional enhancers found in all eukaryotes. A recently reported and novel function for bZIPs is association of these proteins with secondary metabolite production in filamentous fungi. In particular a Yap-like bZIP termed RsmA ( r estorer of s econdary m etabolism A) was identified in Aspergillus nidulans that positively regulates the carcinogen sterigmatocystin. To assess for conserved function for RsmA, we examined a role of this protein in secondary metabolism in the pathogen A. fumigatus. RsmA was found to positively regulate gliotoxin where overexpression (OE) of rsmA led to 2–100 fold increases of twelve gli cluster metabolites in culture medium including the newly identified gli metabolite cyclo(L-Phe-L-Ser). Lungs from both wild type and OErsmA infected mice co
    PLoS ONE 05/2013; 8(5-5):e62591. DOI:10.1371/journal.pone.0062591 · 3.53 Impact Factor